Diving Deeper Into CML is a podcast series looking into the unmet needs in chronic myeloid leukaemia. Our host Dr Ali Mahdi, consultant haematologist at the Aneurin Bevan University Health Board, is joined by a selection of special guests to discuss how healthcare professionals can better improve the management of patients with CML.

Episode 1: Treating patients with CML in the post-pandemic era

 
 

 

UK | July 2021 | 135355

Join Dr Ali Mahdi for the first episode in this series, ‘Treating patients with CML in the post-pandemic era’. Dr Mahdi welcomes Myeloid Advanced Nurse Practitioner Kirsty Crozier and Professor Adam Mead for a discussion on the impact the pandemic has had on monitoring and treatment decisions, how patients have responded to these changes and what the future looks like for CML post-COVID-19.

Reference

  1. Hochhaus A, et al. Leukemia. 2020;34:966–984.

Episode 2: CML monitoring, milestones and optimal management

 
 

 

UK | July 2021 | 142215

Host Dr Ali Mahdi is joined by Professors Jane Apperley and Adam Mead for the second episode in the series, ‘CML monitoring, milestones and optimal management’. This episode covers the need for monitoring in CML, and how ELN and BSH guidelines can support optimal management of patients.

References

  1. Smith G, et al. Br J Haematol. 2020;191:171–193.
  2. Hochhaus A, et al. Leukemia. 2020;34:966–984.
  3. Milojkovic D, et al. Br J Haematol. 2021;192:62–74.

Episode 3: Managing resistance in patients with CML

 
 

 

UK | July 2021 | 142219

Join Dr Ali Mahdi for the third episode in the series, ‘Managing resistance in patients with CML’. In this episode, Dr Mahdi and guests Professors Jane Apperley and Mary Frances McMullin discuss how to recognise resistance and strategies to help overcome it.

References

  1. Hehlmann R, et al. Leukemia. 2017 Nov;31(11):2398–2406.
  2. Wang W, et al. Blood. 2016 Jun 2;127(22):2742–2750.
  3. Hochhaus A, et al. Leukemia. 2020;34:966–984.
  4. Eghtedar A, et al. Clin Lymphoma Myeloma Leuk. 2013;13:477–484.
  5. D’Adda M, Farina M, et al. Cancer. 2019;125(10):1674–1682.

Episode 4: The impact of intolerance on patients with CML

 
 

 

UK | July 2021 | 142220

In the fourth and final episode in this series, ‘The impact of intolerance on patients with CML’, host Dr Ali Mahdi is joined by Professor Mhairi Copland and Dr Priyanka Mehta. They delve into what intolerance to treatment can mean for patients, how it impacts their day-to-day lives and what healthcare professionals can do to minimise that burden.

 

Reference

  1. Hochhaus A, et al. Leukemia. 2020;34:966–984.

 

Click here to sign up to be notified of new episodes to this page specifically. Signing up does not mean you are registered to the portal.

BSH, British Society for Haematology; CML, chronic myelogenous leukaemia; ELN, European LeukemiaNet

Rate this content: 
No votes yet
UK | August 2021 | 122386
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]